vs
ICU MEDICAL INC（ICUI）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
Rithm Capital Corp.的季度营收约是ICU MEDICAL INC的1.5倍（$828.2M vs $540.7M），Rithm Capital Corp.净利率更高（13.2% vs -2.9%，领先16.1%），Rithm Capital Corp.同比增速更快（508.5% vs -14.1%），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -17.9%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
ICUI vs RITM — 直观对比
营收规模更大
RITM
是对方的1.5倍
$540.7M
营收增速更快
RITM
高出522.6%
-14.1%
净利率更高
RITM
高出16.1%
-2.9%
两年增速更快
ICUI
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $828.2M |
| 净利润 | $-15.7M | $109.5M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 29.9% |
| 净利率 | -2.9% | 13.2% |
| 营收同比 | -14.1% | 508.5% |
| 净利润同比 | 34.0% | 27.7% |
| 每股收益（稀释后） | $-0.63 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $540.7M | $1.5B | ||
| Q3 25 | $537.0M | $1.1B | ||
| Q2 25 | $548.9M | $1.2B | ||
| Q1 25 | $604.7M | $768.4M | ||
| Q4 24 | $629.8M | $2.1B | ||
| Q3 24 | $589.1M | $619.5M | ||
| Q2 24 | $596.5M | $1.2B |
净利润ICUIRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $-15.7M | $85.0M | ||
| Q3 25 | $-3.4M | $221.5M | ||
| Q2 25 | $35.3M | $311.7M | ||
| Q1 25 | $-15.5M | $78.8M | ||
| Q4 24 | $-23.8M | $290.2M | ||
| Q3 24 | $-33.0M | $121.7M | ||
| Q2 24 | $-21.4M | $235.6M |
毛利率ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUIRITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | 1.0% | 13.8% | ||
| Q3 25 | 2.6% | 21.4% | ||
| Q2 25 | 1.9% | 25.2% | ||
| Q1 25 | 2.1% | 7.4% | ||
| Q4 24 | 6.0% | 23.8% | ||
| Q3 24 | 1.4% | 7.3% | ||
| Q2 24 | 1.3% | 23.6% |
净利率ICUIRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | -2.9% | 5.7% | ||
| Q3 25 | -0.6% | 20.0% | ||
| Q2 25 | 6.4% | 25.6% | ||
| Q1 25 | -2.6% | 10.3% | ||
| Q4 24 | -3.8% | 14.0% | ||
| Q3 24 | -5.6% | 19.7% | ||
| Q2 24 | -3.6% | 19.2% |
每股收益（稀释后）ICUIRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-0.63 | $0.09 | ||
| Q3 25 | $-0.14 | $0.35 | ||
| Q2 25 | $1.43 | $0.53 | ||
| Q1 25 | $-0.63 | $0.07 | ||
| Q4 24 | $-0.97 | $0.50 | ||
| Q3 24 | $-1.35 | $0.20 | ||
| Q2 24 | $-0.88 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $9.1B |
| 总资产 | $4.1B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $308.6M | $1.5B | ||
| Q3 24 | $312.5M | $1.6B | ||
| Q2 24 | $302.6M | $1.2B |
总债务ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益ICUIRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $2.1B | $8.4B | ||
| Q3 25 | $2.1B | $8.5B | ||
| Q2 25 | $2.1B | $7.9B | ||
| Q1 25 | $2.0B | $7.8B | ||
| Q4 24 | $2.0B | $7.8B | ||
| Q3 24 | $2.0B | $7.7B | ||
| Q2 24 | $2.0B | $7.3B |
总资产ICUIRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $4.1B | $53.1B | ||
| Q3 25 | $4.1B | $47.2B | ||
| Q2 25 | $4.1B | $44.3B | ||
| Q1 25 | $4.2B | $45.3B | ||
| Q4 24 | $4.2B | $46.0B | ||
| Q3 24 | $4.3B | $42.3B | ||
| Q2 24 | $4.3B | $42.0B |
负债/权益比ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $-114.6M | ||
| Q3 25 | $56.7M | $-2.0B | ||
| Q2 25 | $11.2M | $-557.1M | ||
| Q1 25 | $51.3M | $1.4B | ||
| Q4 24 | $40.2M | $-1.8B | ||
| Q3 24 | $36.1M | $768.1M | ||
| Q2 24 | $82.0M | $-55.7M |
自由现金流ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — |
自由现金流率ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — |
资本支出强度ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — |
现金转化率ICUIRITM
| Q1 26 | — | — | ||
| Q4 25 | — | -1.35× | ||
| Q3 25 | — | -9.22× | ||
| Q2 25 | 0.32× | -1.79× | ||
| Q1 25 | — | 18.03× | ||
| Q4 24 | — | -6.04× | ||
| Q3 24 | — | 6.31× | ||
| Q2 24 | — | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
